Acute Lymphoblastic Leukemia News and Research

RSS

Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells, the cells in the body that normally fight infections. There are two main types of white blood cells-lymphoid cells and myeloid cells. ALL affects lymphoid cells.

Leukemic cells find safe haven in bone marrow

The cancer drug asparaginase fails to help cure some children with acute lymphoblastic leukemia (ALL) because molecules released by certain cells in the bone marrow counteract the effect of that drug, according to St. Jude investigators.

16 Apr 2007

New discovery suggests novel methods for treating acute lymphoblastic leukemia

Investigators at St. Jude Children's Research Hospital have discovered previously unsuspected mutations that contribute to the formation of pediatric acute lymphoblastic leukemia (ALL), the most common cancer in children.

8 Mar 2007

Researchers discover clues to the cause of T-cell acute lymphoblastic leukemia

Researchers' discovery of clues to the cause of T-cell acute lymphoblastic leukemia (T-ALL) - a form of pediatric cancer that has a very poor prognosis - could lead to the development of new targeted therapies for this extremely difficult disease.

20 Sep 2006

FDA expands use of Oncaspar to include treating children and adults with newly diagnosed acute lymphoblastic leukemia

The U.S. Food and Drug Administration (FDA) has expanded the approved use of Oncaspar to include treating children and adults with newly diagnosed acute lymphoblastic leukemia (ALL) as part of a multiple drug chemotherapy regimen.

25 Jul 2006

FDA grants accelerated approval for Sprycel (dasatinib)

FDA grants accelerated approval for Sprycel (dasatinib), a new oral treatment for patients with chronic myeloid leukemia (CML),

29 Jun 2006

Finding indicate why some kinds of Leukemia are more aggressive than others

New clues to why some kinds of leukemia are more aggressive and deadly than others are coming from research examining the types of genetic damage that allow some blood cells to grow out of control, scientists report.

28 Apr 2006

Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia

23 Apr 2006

miR 155 overexpression can lead to cancer

Scientists in the Ohio State University Comprehensive Cancer Center say that just one, single, malfunctioning microRNA is sufficient to cause cancer in mice.

18 Apr 2006

Dasatinib provides significant benefit in chronic myeloid leukemia patients resistant to Gleevec

A study led by researchers from the Howard Hughes Medical Institute has found that dasatinib provides significant benefit in chronic myeloid leukemia (CML) patients resistant to Gleevec. (imatinib), according to a study presented during the 97th Annual Meeting of the American Association for Cancer Research.

11 Apr 2006

St. Jude develop relatively simple and inexpensive test for acute lymphoblastic leukemia

Investigators at St. Jude Children's Research Hospital have developed a relatively simple and inexpensive test that identifies children with acute lymphoblastic leukemia (ALL) who have responded well enough to their first round of chemotherapy that they might be successfully treated with a much less aggressive follow-up treatment.

3 Apr 2006

St. Jude projects 90 percent cure rate for acute lymphoblastic leukemia

The cure rate for the once almost universally fatal childhood cancer acute lymphoblastic leukemia (ALL) could reach 90 percent in the near future, thanks to improvements in diagnosis and treatment over the past four decades, according to investigators at St. Jude Children's Research Hospital.

11 Jan 2006

Infections are a major cause of childhood cancer

Results from a new study of childhood cancer statistics provide further evidence that common infections affecting mother and baby could play a key role in triggering certain types of the disease.

12 Dec 2005

New monoclonal antibody that targets immune system B cells shows promise for treating leukemias

In studies with mice, treatment with a new monoclonal antibody that targets immune system B cells has shown considerable promise for treating leukemias, autoimmune diseases and transplant rejection, according to immunologists at Duke University Medical Center.

11 Oct 2005

Important milestone towards more individually targeted and effective treatments for cancer patients

The research team has now identified crucial genes in a range of common cancers that have been reported to predict a patient's response to treatment. This follows the team's earlier success in studying a tumor suppressor gene associated with acute lymphoblastic leukaemia (ALL) in children.

9 Oct 2005

Study looks at childrens end-of-life care preferences

Pediatric cancer patients as young as 10 years old who are aware that their disease is incurable have the ability to participate meaningfully in discussions of their own end-of-life care with family members and the health care team, according to investigators at St. Jude Children's Research Hospital and Sydney Children's Hospital.

5 Oct 2005

$4.7million grant for research on neuroblastoma

Significant funding from Australia's National Health and Medical Research Council will enable researchers at Children’s Cancer Institute Australia (CCIA) for Medical Research to make progress on the treatment of one the most aggressive, drug-resistant childhood cancers - neuroblastoma - over the next five years.

28 Jul 2005

New study shows tiny RNAs intimately associated with cancer

In discoveries that may open a new chapter in understanding and diagnosing cancer, Howard Hughes Medical Institute (HHMI) investigators and their colleagues have established that tiny microRNAs provide a novel genetic route to the initiation of some forms of cancer.

9 Jun 2005

Childhood cancer in relation to distance from high voltage power lines - results may be entirely due to chance

Cancer Research UK comments on the BMJ paper "Childhood cancer in relation to distance from high voltage power lines in England and Wales: a case control study."

3 Jun 2005

Genetics may play a role in the effectiveness of chemotherapy drugs

Today, the most common childhood cancer is cured in about 80 percent of patients; only forty years ago, this number was closer to five percent. In efforts to further increase the survival rate, researchers from St. Jude Children's Research Hospital, the University of Tennessee, and the University of Chicago studied how an individual's genetics might play a role in the effectiveness of chemotherapy drugs.